Show simple item record

dc.contributor.authorRichards, MW
dc.contributor.authorBurgess, SG
dc.contributor.authorPoon, E
dc.contributor.authorCarstensen, A
dc.contributor.authorEilers, M
dc.contributor.authorChesler, L
dc.contributor.authorBayliss, R
dc.date.accessioned2017-03-24T14:24:28Z
dc.date.issued2016-11-29
dc.identifier.citationProceedings of the National Academy of Sciences of the United States of America, 2016, 113 (48), pp. 13726 - 13731
dc.identifier.issn0027-8424
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/498
dc.identifier.eissn1091-6490
dc.identifier.doi10.1073/pnas.1610626113
dc.description.abstractMyc family proteins promote cancer by inducing widespread changes in gene expression. Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosphorylation of Myc Box I and ubiquitination by the E3 ubiquitin ligase SCFFbxW7 However, N-Myc protein (the product of the MYCN oncogene) is stabilized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds SCFFbxW7 We determined the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-Å resolution. The structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD532 is not compatible with the binding of N-Myc, explaining the activity of these compounds in neuroblastoma cells and providing a rational basis for the design of cancer therapeutics optimized for destabilization of the complex. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCFFbxW7 to disfavor the generation of Lys48-linked polyubiquitin chains.
dc.formatPrint-Electronic
dc.format.extent13726 - 13731
dc.languageeng
dc.language.isoeng
dc.publisherNATL ACAD SCIENCES
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPhenylurea Compounds
dc.subjectAzepines
dc.subjectPyrimidines
dc.subjectSKP Cullin F-Box Protein Ligases
dc.subjectPolyubiquitin
dc.subjectProtein Kinase Inhibitors
dc.subjectCrystallography, X-Ray
dc.subjectBinding Sites
dc.subjectCatalytic Domain
dc.subjectProtein Binding
dc.subjectPhosphorylation
dc.subjectAurora Kinase A
dc.subjectN-Myc Proto-Oncogene Protein
dc.titleStructural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
dc.typeJournal Article
dcterms.dateAccepted2016-11-29
rioxxterms.versionofrecord10.1073/pnas.1610626113
rioxxterms.licenseref.startdate2016-11-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfProceedings of the National Academy of Sciences of the United States of America
pubs.issue48
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics
pubs.publication-statusPublished
pubs.volume113
pubs.embargo.termsNot known
icr.researchteamPaediatric Solid Tumour Biology and Therapeutics
dc.contributor.icrauthorPoon, Evon
dc.contributor.icrauthorChesler, Louis


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record